ERAP1 allotypes shape the epitope repertoire of virus-specific CD8+ T cell responses in acute hepatitis C virus infection by Kemming, Janine et al.
Research Article
JOURNAL 
OF HEPATOLOGYERAP1 allotypes shape the epitope repertoire
of virus-specific CD8+ T cell responses in acute
hepatitis C virus infectionGraphical abstracthttp://dx.doi.org/10.1016/j.jhep.2019.01.034
 2019 European Association for the Study of the Liver. Published by Elsevier B.V
license (http://creativecommons.org/licenses/by-nc-nd/4.0/). J. Hepatol. 2019, 70, 10AuthorsGRAAICGKY
Epitope trimming
 1PARE yb Cell surface presentation Epitope repertoire 
Outcome of HCV
infection in HLA-
B*27+ patients
 tneiciffE 9-mer epitopes Conservedimmunodominance  
80% spontaneous
resolution 
Hypoactive 10-/11-mer epitopes Skewedimmunodominance
Low-viremic
persistent course
Highlights
 ERAP1 polymorphisms are strongly linked with HLA class
I-associated autoinflammatory disorders.
 We identified 2 hypoactive ERAP1 allotypes in an
HLA-B*27:05+ individual with acute HCV infection.
 These ERAP1 allotypes modified the HCV-specific CD8+ T cell
epitope repertoire in vivo, leading to altered immunodom-
inance patterns.
 Altered immunodominance patterns potentially contributed
to the failure of antiviral immunity.Janine Kemming, Emma Reeves, Katja
Nitschke, ..., Robert Thimme, Edward
James, Christoph Neumann-Haefelin
Correspondence
christoph.neumann-haefelin@uniklinik-
freiburg.de (C. Neumann-Haefelin)
Lay summary
Endoplasmic reticulum aminopeptidase 1
(ERAP1) plays a key role in antigen pre-
sentation. Genetic variants of ERAP1
(leading to distinct allotypes) are linked
with specific autoinflammatory disorders,
such as ankylosing spondylitis and
Behçet’s disease. We found that ERAP1
allotypes modified the repertoire of virus-
specific CD8+ T cell epitopes in a patient
with hepatitis C virus, leading to an
altered pattern of immunodominance
that may have contributed to the failure
of antiviral immunity in this patient.Viral Hepatitis. This is an open access article under the CC BY-NC-ND
72–1081
hc
7
,
lt
nc
;
, G
n
in
JOURNAL 
OF HEPATOLOGY
Research Article
Viral HepatitisERAP1 allotypes shape the epitope
T cell responses in acute
Janine Kemming1,2,y, Emma Reeves3,y, Katja Nits
Tobias Hermle5, Emma Gostick6, Andreas Walker
Robert Thimme1, Edward James3,
1Department of Medicine II, University Medical Center Freiburg, Facu
Biology, University of Freiburg, Freiburg, Germany; 3Centre for Ca
University Hospital Southampton, Southampton, United Kingdom
Hospital Freiburg, Faculty of Medicine, University of Freiburg, Freiburg
of Medicine, University of Freiburg, Freiburg, Germany; 6Division of I
United Kingdom; 7Institute for Virology, He
Background & Aims: Endoplasmic reticulum aminopeptidase 1
(ERAP1) polymorphisms are linked with human leukocyte anti-
gen (HLA) class I-associated autoinflammatory disorders,
including ankylosing spondylitis and Behçet’s disease. Disease-
associated ERAP1 allotypes exhibit distinct functional proper-
ties, but it remains unclear how differential peptide trimming
in vivo affects the repertoire of epitopes presented to CD8+ T
cells. The aim of this study was to determine the impact of
ERAP1 allotypes on the virus-specific CD8+ T cell epitope reper-
toire in an HLA-B*27:05+ individual with acute hepatitis C virus
(HCV) infection.
Methods:We performed genetic and functional analyses of
ERAP1 allotypes and characterized the HCV-specific CD8+ T cell
repertoire at the level of fine epitope specificity and HLA class I
restriction, in a patient who had acquired an HCV genotype 1a
infection through a needle-stick injury.
Results: Two hypoactive allotypic variants of ERAP1 were iden-
tified in an individual with acute HCV infection. The associated
repertoire of virus-derived epitopes recognized by CD8+ T cells
was uncommon in a couple of respects. Firstly, reactivity
was directed away from classically immunodominant epitopes,
preferentially targeting either novel or subdominant
epitopes. Secondly, reactivitywas biased towards longer epitopes
(10–11-mers). Despite the patient exhibiting favorable
prognostic indicators, these atypical immune responses failed
to clear the virus and the patient developed persistent low-
level infection with HCV.
Conclusions: ERAP1 allotypes modify the virus-specific CD8+ T
cell epitope repertoire in vivo, leading to altered immunodomi-
nance patterns that may contribute to the failure of antiviral
immunity after infection with HCV.
Keywords: Epitope repertoire; ERAP1; Hepatitis C virus; HLA-B*27; T cells.
Received 25 June 2018; received in revised form 30 January 2019; accepted 31 January
2019; available online 13 February 2019
⇑ Corresponding author. Address: University Hospital Freiburg, Department of
Medicine II, Hugstetter Strasse 55, 79106 Freiburg, Germany. Tel.: +49-761-270-
32800, fax: +49-761-270-32800.
E-mail address: christoph.neumann-haefelin@uniklinik-freiburg.de (C. Neumann-
Haefelin).
y Equally contributing first authors.
 Equally contributing last authors.Journal of Hepatology 2repertoire of virus-specific CD8+
epatitis C virus infection
hke1, Vanessa Widmeier1, Florian Emmerich4,
, Jörg Timm7, David A. Price6, Maike Hofmann1,
Christoph Neumann-Haefelin1,⇑,
y of Medicine, University of Freiburg, Freiburg, Germany; 2Faculty of
er Immunology, Faculty of Medicine, University of Southampton,
4Institute of Transfusion Medicine and Gene Therapy, University
ermany; 5Renal Division, University Medical Center Freiburg, Faculty
fection and Immunity, Cardiff University School of Medicine, Cardiff,
rich Heine University, Düsseldorf, Germany
Lay summary: Endoplasmic reticulum aminopeptidase 1
(ERAP1) plays a key role in antigen presentation. Genetic vari-
ants of ERAP1 (leading to distinct allotypes) are linked with
specific autoinflammatory disorders, such as ankylosing
spondylitis and Behçet’s disease. We found that ERAP1 allotypes
modified the repertoire of virus-specific CD8+ T cell epitopes in
a patient with hepatitis C virus, leading to an altered pattern of
immunodominance that may have contributed to the failure of
antiviral immunity in this patient.
 2019 European Association for the Study of the Liver. Published by
Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Endoplasmic reticulum aminopeptidase 1 (ERAP1) trims pep-
tides to an optimal length (usually 8 or 9 amino acids) for pre-
sentation in the context of human leukocyte antigen (HLA)
class I molecules.1,2 Genome-wide association studies have
identified single nucleotide polymorphisms (SNPs) in ERAP1
as important risk factors in several HLA class I-associated
autoinflammatory disorders,3 including ankylosing spondyli-
tis,4 especially in conjunction with HLA-B*27,5 and Behçet’s
disease, which is strongly linked with HLA-B*51.6 In addition,
SNPs in ERAP1 can combine to encode discrete allotypes with
composite functional properties that further increase the risk
of disease.7 Biochemical analyses have revealed differential
peptide trimming among ERAP1 allotypes, with hypoactive
forms typically generating longer fragments (10–12-mers),
and hyperactive forms typically generating shorter fragments
(7–8-mers).8–10 However, the impact of specific ERAP1 allo-
types on the naturally presented repertoire of peptide epitopes
is currently unclear.11
Hepatitis C virus (HCV) has infected approximately 71
million people worldwide. Persistent infection ensues in
50–80% of cases, with a high risk of liver disease, which may
progress to cirrhosis, liver failure, and hepatocellular
carcinoma.12 Virus-specific CD8+ T cells are thought to play a
key role in immune protection against HCV.13 This consensus
is predicated on associative studies that have linked viral019 vol. 70 j 1072–1081
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and the presence of certain HLA class I allotypes.14 In particular,
up to 80% of HLA-B*27+ individuals clear HCV spontaneously,
contrasting with only 20–50% of individuals in the general popu-
lation.15 We previously attributed this protective effect to the
immunodominant HLA-B*27-restricted CD8+ T cell epitope
NS5B2841-2849 (ARMILMTHF), which is targeted in almost all
HLA-B*27+ individuals during acute infection with HCV.16,17
In this study, we performed a comprehensive analysis of
ERAP1 allotypes and virus-specific CD8+ T cell responses in an
HLA-B*27:05+ individual with acute HCV infection. Despite a
symptomatic presentation, expression of HLA-B*27, and a favor-
able interleukin 28B (IL28B)/interferon lambda 4 (IFNL4) geno-
type, all of which predict viral clearance, this individual
progressed to chronic infection, with low-level viremia (mostly
<100 IU/ml) throughout a follow-up period of 20 months before
the initiation of antiviral therapy. In-depth genetic, biochemical,
and immunological analyses revealed the presence of ERAP1
allotypes with hypoactive trimming functions, which shaped
the epitope repertoire to elicit atypical HCV-specific CD8+ T cell
responses.
Patients and methods
Samples
A donor (MM) with acute HCV genotype 1a infection acquired
via needle-stick injury was recruited after providing written
informed consent in line with federal guidelines and the Decla-
ration of Helsinki. Ethical approval for this study was obtained
from the Ethik-Kommission der Albert-Ludwigs-Universität
Freiburg (#524/14). Venous blood samples (50 ml per draw)
were collected in ethylene diamine tetraacetic acid (EDTA)-
anticoagulated tubes at longitudinal time points. Peripheral
blood mononuclear cells (PBMCs) were isolated using lympho-
cyte separation medium density gradients (PAA Laboratories,
Austria) and resuspended in Roswell Park Memorial Institute
(RPMI) 1640 medium supplemented with 10% fetal calf serum,
1% streptomycin/penicillin, and 1.5% HEPES buffer 1 M (com-
plete medium; all additives from Thermo Fisher Scientific,
Germany).Peptides, antibodies, and multimers
Overlapping peptides (mostly 15 amino acids each, overlapping
by 11 amino acids) spanning the entire polyprotein of HCV
strain H77 (genotype 1a) were obtained from BEI Resources
(Manassas, VA, USA) via the National Institute of Allergy and
Infectious Diseases (Bethesda, MD, USA). Additional peptides
were synthesized with a free amine NH2 terminus and a free
acid COOH terminus using standard Fmoc chemistry (Genaxxon
Bioscience, Germany). The viability dye 7-aminoactinomycin D
(7-AAD) and the directly conjugated monoclonal antibodies
(mAbs) anti-CD8-PE (clone RPA-T8), anti-CD8-APC (clone SK1),
anti-CD8-BV421 (clone RPA-T8), and anti-IFN-c-FITC (clone
25723.11) were obtained from BD Biosciences (Germany). Mul-
timeric complexes of HLA-B*27:05/NS5B2936-2944 (GRAAICGKY)
and HLA-B*27:05/NS5B2936-2946 (GRAAICGKYLF) were generated
as described previously.18
CD8 selection and polyclonal expansion of PBMCs
Procedures were carried out as described previously.19 More
details may be found in the supplementary information.
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PBMCs were activated with peptides as described previously.17
More details may be found in the supplementary information.
Enzyme-linked immunospot assay
An IFN-c enzyme-linked immunospot (ELISpot) kit (Diaclone,
France) was used to quantify peptide-specific T cells as
described previously.17 Peptides were distributed across 92
pools in a matrix format (n = 10 peptides per pool). Each peptide
was present in 2 different pools, allowing identification of speci-
fic responses to individual peptides. Tests with peptide pools
were performed in duplicate. In each assay, negative control
wells (n = 4) contained medium alone, and positive control
wells (n = 4) contained medium supplemented with phyto-
hemagglutinin or phorbol 12-myristate 13-acetate (PMA) and
ionomycin (Sigma-Aldrich, Germany). Responses were consid-
ered positive if the mean number of spots per test well was at
least 3 times as high as the mean number of spots per negative
control well. Positive responses were confirmed by intracellular
IFN-c staining with single peptides.
Intracellular IFN-c staining
Procedures were carried out as described previously.20 More
details may be found in the supplementary information.
HLA/peptide multimer staining
Procedures were carried out as described previously.21 More
details may be found in the supplementary information.
Isolation and cloning of ERAP1 allotypes
ERAP1 was amplified from donor complementary DNA as
described previously.7,10 The amplicon was cloned into
pcDNA3.1TM (Invitrogen, UK) and sequenced to identify both
chromosomal allotypes of ERAP1. Sequences from donor MM
were compared with the prototype (PT) ERAP1 using DNADy-
namo alignment software (Blue Tractor Software, UK).
DNA constructs
The pcDNA3.1 minigenes (ES)-SHL8 and (ES)-X-SHL8 were engi-
neered to encode an endoplasmic reticulum (ER) targeting sig-
nal sequence.10 The pcDNA3.1-(ES)-SRG-SHL8 construct was
generated via the incorporation of an additional nucleotide
sequence encoding serine, arginine, and glycine (SRG) in
pcDNA3.1-(ES)-SHL8, engineered using the primers 50-CTTGCG
GCAGTCTGCAGCGCGAGCCGTGGCAGCATCATCAACTTCGAGCAC-
30 and 50-GTGCTCGAAGTTGATGATGCTGCCACGGCTCGCGCTGCA
GACTGCCGCAAG-30. Three HCV epitope-specific constructs
were generated via the insertion of oligonucleotides into the
EcoRI/XbaI sites of pcDNA3.1, encoding an ER translocation sig-
nal sequence followed by the amino acid sequences
GRAAICGKY, SRGGRAAICGKY, or GRAAICGKYLF. Plasmid con-
structs encoding PT ERAP1, E320A non-functional ERAP1, and
HLA-B*27:05 were described previously.7 All constructs were
sequence-verified using DNADynamo alignment software (Blue
Tractor Software, UK).
Cell lines and transfections
ERAP1 knock-out 293T (293T E1KO) cells were transfected using
the FuGENE 6 Transfection Reagent (Promega, UK).7 For assess-
ment of ERAP1 trimming activity, 293T E1KO cells were trans-
fected with 1 lg total DNA, consisting of 0.5 lg PT ERAP1,19 vol. 70 j 1072–1081 1073
0.5 lg E320A non-functional ERAP1, or 0.25 lg of each MM
allotype-encoded ERAP1, together with 0.25 lg H2-Kb and
0.25 lg SHL8 or the extended precursor SRG-SHL8. For assess-
ment of ERAP1 amino acid specificity, 293T E1KO cells were
transfected with 0.1 lg total DNA, consisting of 0.05 lg MM
allotype-encoded ERAP1, 0.025 lg H2-Kb, and 0.025 lg
X-SHL8. All transfected cells were incubated for 24 h at 37 C.
Presentation of trimmed SHL8 and activation of the
LacZ-inducible B3Z T cell hybridoma were assessed by measure-
ment of intracellular LacZ activity using the substrate
chlorophenol red-b-d-galactopyranoside (Roche, UK).10
Activation of donor MM T cells
The 293T E1KO cells were transfected with 1 lg total DNA, con-
sisting of 0.5 lg ERAP1, 0.25 lg HLA-B*27:05, and 0.25 lg
GRAAICGKY, SRGGRAAICGKY, or GRAAICGKYLF. Transfected
cells were incubated for 24 h, harvested, and cultured for a fur-
ther 24 h with donor MM T cells at an effector-to-target ration
of 3:1. Activation of donor MM T cells was determined by IFN-
c staining as described.
Statistical analysis
Differences among multiple groups were evaluated for signifi-
cance using a 1-way ANOVA with Dunnett’s post hoc test imple-
mented in GraphPad Prism (www.graphpad.com).
For further details regarding the materials used, please refer
to the CTAT table and supplementary information.
Results
Persistent low-level viremia after infection with HCV despite
multiple predictors of spontaneous viral clearance
Donor MM experienced an accidental needle-stick injury from
an HCV genotype 1a-infected patient and developed symp-
tomatic HCV infection over a period of 20 months (Fig. 1). Seven
weeks after the needle-stick injury, alanine aminotransferase
peaked at 1,307 U/L, viremia peaked at 1.15  107 IU/ml, HCV-
specific antibodies became detectable in the serum, and the
donor suffered from fatigue, nausea, and moderate jaundice
(bilirubin peaked at 5.3 mg/dl). Further virological analyses con-
firmed infection with HCV genotype 1a. Genetic analyses
revealed that donor MM had the favorable IFNL4 (previously
named IL28B) genotype CC (SNP rs12979860) and expressed
the HLA class I molecules A*01:01, A*26:01, B*08:01, and
B*27:05. Three positive predictors of spontaneous viral clear-
ance were therefore present in this individual, namely symp-
tomatic infection,22 IFNL4 genotype CC,23 and HLA-B*27.15
However, donor MM continued to display moderately elevated
liver enzymes and remained positive for HCV RNA, albeit below
the lower level of quantification (LLOQ, 12 IU/ml). In addition,
donor MM suffered from oscillating complaints, including sub-
febrile temperatures and flu-like symptoms. After 20 months,
treatment was initiated with direct-acting antivirals (DAAs),
leading to normalization of liver enzymes, clearance of the virus
(negative HCV RNA 12 and 24 weeks after discontinuation of
DAAs) and resolution of symptoms.
Lack of viral clearance associated with altered HCV-specific
CD8+ T cell responses
To determine the immunological correlates of persistent infec-
tion in donor MM, we performed a comprehensive analysis of
HCV-specific CD8+ T cell responses, which are thought to play
a key role in viral clearance.13 We used 460 overlapping pep-
tides (OLPs) spanning the complete HCV genotype 1a polypro-
tein and performed IFN-c ELIspot assays in a matrix
format.24,25 Positive responses were confirmed individually by
intracellular staining for IFN-c. Using this approach, we identi-
fied 6 HCV-specific CD8+ T cell responses in donor MM (OLP-77,
OLP-203, OLP-209/210, OLP-211, OLP-323/324, and OLP-
450/451; Fig. 2 and Table 1).
The responses elicited by OLP-209/210, OLP-211, and OLP-
450/451 potentially targeted previously described epitopes
restricted by HLA-A*26:01 (NS31383-1391, EVIKGGRHL),26 HLA-
B*08:01 (NS31395-1403, HSKKKCDEL),27,28 and HLA-B*27:05
(NS5B2936-2944, GRAAICGKY).
17,29We therefore tested these opti-
mal 9-mer epitopes in peptide-specific cell lines. Unexpectedly,
we only observed a response to NS31395-1403 (HSKKKCDEL), cor-
responding to OLP-211 (Fig. 2). Responses to NS31383-1391
(EVIKGGRHL) and NS5B2936-2944 (GRAAICGKY) were either
absent or very weak (Fig. 2). Using Epstein-Barr virus-
immortalized B cell lines partially matched for HLA class I, we
confirmed that CD8+ T cells targeting OLP-209/210 were
restricted by HLA-A*26:01 (Fig. 3A and 3B), and that CD8+ T cells
targeting OLP-450/451 were restricted by HLA-B*27:05 (Fig. 3C).
These findings suggested that CD8+ T cells from donor MM were
specific for length variants of NS31383-1391 (EVIKGGRHL) and
NS5B2936-2944 (GRAAICGKY). We therefore performed in vitro
analyses using peptides of different lengths. For both reactivities,
the cognate epitopes were defined by 11-mer peptides (Fig. 3D
and 3E; Table 2). The immunodominant response to the extended
HLA-B*27:05-restricted 11-mer peptide GRAAICGKYLF was fur-
ther confirmed using HLA-B*27:05/peptide multimers. In dual
staining experiments, the HLA-B*27:05/GRAAICGKYLF multimer
identified substantially higher frequencies of cognate CD8+ T
cells among PBMCs from donor MM at week 10 and week 32
post-infection compared with the HLA-B*27:05/GRAAICGKY
multimer (Fig. 3F, upper panel), whereas the HLA-B*27:05/
GRAAICGKYmultimer identified substantially higher frequencies
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Fig. 1. Clinical course of HCV infection in donor MM. The needle-stick
injury was set as day 0. HCV, hepatitis C virus; LLOQ, lower level of
quantification (12 IU/ml); ULN, upper limit of normal (50 U/L).1074 Journal of Hepatology 20of cognate CD8 T cells among PBMCs from 2 HLA-B*27:05
donors with resolved HCV infection compared with the HLA-
B*27:05/GRAAICGKYLF multimer (Fig. 3F, lower panel).
The responses elicited by OLP-77, OLP-203, and OLP-323/324
did not correspond with previously described HCV-specific19 vol. 70 j 1072–1081
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Table 1. Summary of responses to OLPs and previously described HCV-specific epitopes in donor MM.
Peptide HCV location Peptide aa sequence HLA restriction
OLP77 E2511-527 PSPVVVGTTDRSGAPTY A*01:01
OLP203 NS31336-1353 AETAGARLVVLATATPPG A*26:01
OLP209 NS31376-1393 YGKAIPLEVIKGGRHLIF A*26:01
OLP210 NS31383-1399 EVIKGGRHLIFCHSKKK
predescribed NS31383-1391 EVIKGGRHL
OLP211 NS31389-1406 RHLIFCHSKKKCDELAKK B*08:01
pt
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OF HEPATOLOGYCD8+ T cell epitopes. In silico and in vitro analyses revealed 3
novel reactivities: (i) OLP-77 – HLA-A*01:01-restricted 10-mer
epitope (E2518-527, TTDRSGAPTY; Fig. S1A and S1B); (ii)
OLP-203 – HLA-A*26:01-restricted 11-mer epitope
predescribed NS31395-1403
OLP323 NS5A2124-2141
OLP324 NS5A2131-2148
predescribed NS5B2841-2849
OLP450 NS5B2930-2946
OLP451 NS5B2936-2953
predescribed NS5B2936-2944
Optimal epitopes are indicated in bold. HCV, hepatitis C virus; OLPs, overlapping pe(NS31337-1347, ETAGARLVVLA; Fig. S1C and S1D); and (iii)
Journal of Hepatology 20OLP-323/324 – HLA-B*27:05-restricted 11-mer epitope
(NS5A2131-2141, HRFAPPCKPLL; Fig. S1E and S1F; Table 2).
Surprisingly, we did not observe HCV-specific CD8+ T cell
responses to overlapping peptides incorporating the previously
HSKKKCDEL
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GRAAICKGY
ides.defined immunodominant epitopes NS31436-1444 (ATDALMTGY,
19 vol. 70 j 1072–1081 1075
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Research Article Viral Hepatitisrestricted by HLA-A*26:01), or NS5B2841-2849 (ARMILMTHF,
restricted by HLA-B*27:05).17,26,27 To confirm the absence of
these epitope-specific responses, we tested the optimal 9-mer
peptides in intracellular IFN-c staining assays. A weak response
was detected against ARMILMTHF (Fig. 2), but no responses
were detected against ATDALMTGY or DVVCCSMSY (Fig. S2).
Our detailed analysis of HCV-specific CD8+ T cell responses in
donor MM therefore revealed that: (i) reactivity was directed
away from typically immunodominant epitopes, preferentially
targeting either novel or subdominant epitopes; and (ii) reactiv-
ity was biased towards longer epitopes (10–11-mers) (Table 2).1076 Journal of Hepatology 20variants of ERAP1
The immunoreactivity patterns identified in donor MM sug-
gested either that the previously described optimal epitopes
were not presented or that the longer targeted epitopes were
more abundant on the surface of infected cells. We therefore
hypothesized a determinative role for hypoactive allotypes of
ERAP1, which allow surface expression of C-terminally
extended peptides in the context of HLA class I.8 Molecular clon-
ing revealed the presence of 2 ERAP1 allotypes in this donor
(Fig. 4A): (i) ERAP1*001 (P127, V349, R528, N575, Q725,
E730), a known hypoactive variant;7 and (ii) a previously19 vol. 70 j 1072–1081
ifi
in
25
 
 
 
JOURNAL 
OF HEPATOLOGYTable 2. Epitopes targeted in donor MM and previously described HCV-spec
MM.
HLA allele Described HCV-specific epitopes (immunodominant epitopes
A*01:01 NS31436-1444 ATDALMTGY 9-mer
A*26:01 NS31383-1391 EVIKGGRHL 9-mer
NS31582-1590 ENLPYLVAY 9-mer
NS3/4A1654-1662 EVVTSTWVL 9-mer
NS5A/B2416-2424 DVVCCSMSY 9-mer
NS31337-1347
B*08:01 NS31395-1403 HSKKKCDEL 9-mer
NS31402-1410 ELAAKLVAL 9-mer
NS31611-1618 LIRLKPTL 8-mer
B*27:05 P7780-788 GRWVPGAAY 9-mer
NS31492-1501 GRGKPGIYRF 10-mer
NS5B2841-2849 ARMILMTHF 9-mer
NS5B2936-2944 GRAAICGKY 9-mer
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(K56, P127, R528, E730). To determine the trimming function
of these 2 ERAP1 allotypes individually and in combination,
we used the well characterized SIINFEHL (SHL8) murine model
system, in which an ER-targeted N-terminally extended precur-
sor of SHL8 was transfected into 293T E1KO cells alongside each
or both allotypes of ERAP1. The expression of trimmed SHL8
presented by H2-Kb on the cell surface was measured via stim-
ulation of the SHL8-specific LacZ reporter T cell hybridoma B3Z.
We further related these experiments to the poor immuno-
genicity of GRAAICGKY in donor MM by using an N-terminally
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presented by H2-Kb on the cell surface was measured via stimulation of the SHL
activation of B3Z with increasing numbers of target cells. (C) Results norma
experiments ± SEM. 1-way ANOVA with Dunnett’s post hoc test was performed.
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E320Aextended version of SHL8 (SRG-SHL8) corresponding to the pre-
dicted precursor peptide generated via proteasomal cleavage of
the parent protein NS5B (SRG-GRAAICGKY). As shown in Fig. 4B
and 4C, both ERAP1 allotypes expressed by donor MM were
hypoactive, with trimming activities between those of the neg-
ative control (a non-functional ERAP1 variant known as E320A,
which carries a mutation in the active-site GAMEN motif) and
the prototype (PT) control (ERAP1*002). Similar trimming effi-
ciencies were observed with both allotypes in combination
(Fig. 4B and 4C). To analyze the effect of these allotypes on
trimming in the context of other HCV-derived epitopes, we
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MM. (A) ERAP1 allotypes expressed in donor MM vs. the PT control allotype
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ensions (X-SHL8). Results are normalized to the response observed with SHL8,
dependent experiments ± SEM.
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ent N-terminal extensions (X-SHL8). The combined ERAP1 allo-
types of donor MM again performed suboptimally in most cases
(Fig. 4D), displaying marked hierarchical differences compared
D CD8
0
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%
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u
ewith the trimming activity of ERAP1*002.10 The altered immun-
odominance pattern in donor MM therefore correlated with the
expression of 2 hypoactive variants of ERAP1.
Differential generation of the GRAAICGKYLF epitope by
allotypic variants of ERAP1
To extend these findings, we transfected 293T E1KO cells with:
(i) HLA-B*27:05; (ii) minigenes expressing the 9-mer
GRAAICGKY, the 11-mer GRAAICGKYLF, or an N-terminally
extended 12-mer precursor of the 9-mer epitope (SRG-
GRAAICGKY); and DNA encoding (iii) the non-functional ERAP1
variant (E320A), the active PT control ERAP1*002, or the donor
MM allotypes ERAP1*001 and ERAP1*014. Presentation of the
11-mer epitope by HLA-B*27:05 on the surface of transfected
cells was measured using a GRAAICGKYLF-specific CD8+ T cell
line from donor MM. We first confirmed that CD8+ T cells from
donor MM failed to recognize the 9-mer epitope, irrespective of
the N-terminal sequence and the expressed ERAP1 allotype
(Fig. 5A, 5C, and 5D). As expected, transfection of the 11-mer
peptide minigene with inactive ERAP1 generated a strong
response (Fig. 5B, left panel), whereas cells expressing the PT
control ERAP1*002 elicited a significantly weaker response, con-
sistent with overtrimming and destruction of GRAAICGKYLF
(Fig. 5B, middle panel). Interestingly, cells expressing the ERAP1
allotypes from donor MM also elicited a strong response, indi-
cating preservation of GRAAICGKYLF (Fig. 5B, right panel). The
immunodominant 9-mer epitope was therefore generated from
an N-terminally extended precursor, but not from a
C-terminally extended precursor, in the presence of functional
ERAP1. In the presence of hypoactive ERAP1, however, the
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1078 Journal of Hepatology 20N-terminally extended precursor was not trimmed to the opti-
mal length, hence the absence of the usual 9-mer peptide,
whereas the C-terminally extended 11-mer version escaped
destruction to prime and activate virus-specific CD8+ T cells.
Additional factors that may impact immunodominance
patterns
Immunodominance patterns can be influenced by factors other
than antigen presentation.31 Donor MM was infected with a
viral strain that contained nonsynonymous mutations in 4 of
the previously described epitopes restricted by HLA-A*01:01,
HLA-A*26:01, HLA-B*08:01, or HLA-B*27:05 (Table S1). How-
ever, the typically immunodominant HLA-B*27:05-restricted
epitope NS5B2841-2849 (ARMILMTHF) incorporated a conserva-
tive isoleucine to valine switch at position 4 (ARMVLMTHF),
which did not affect immune recognition (Fig. S3), consistent
with a previous report.16 In contrast, the typically immunodom-
inant HLA-A*01:01-restricted epitope NS31436-1444
(ATDALMTGY) incorporated a tyrosine to phenylalanine switch
at the C-terminus (ATDALMTGF), which has been shown previ-
ously to escape immune recognition.32 Therefore, the lack of
ATDALMTGY-specific CD8+ T cells in donor MM likely reflected
sequence variation in the infecting viral strain rather than SNPs
in ERAP1. Competition among epitopes and cognate CD8+ T cell
avidity can also affect immunodominance patterns. In donor
MM, epitopes restricted by HLA-B*08:01, an HLA allele that usu-
ally restricts dominant CD8+ T cell responses in HCV infection,
were only weakly targeted. The immundominant HLA-
B*27:05-restricted epitope NS5B2936-2946 (GRAAICGKYLF), how-
ever, was targeted with relatively high avidity (Fig. S4), but it
remains to be determined if this attribute contributed to the
numerical dominance of GRAAICGKYLF-specific CD8+ T cells. It
is also important to point out, however, that the virus-specific
CD8+ T cell responses in donor MM decreased in strength over
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unchanged even at week 68 after infection (Fig. S5).
Discussion
ERAP1 has garnered interest as a consequence of genetic associ-
ations with several autoinflammatory disorders, such as anky-
losing spondylitis, birdshot chorioretinopathy, psoriasis, and
Behçet’s disease.3 Epistatic interactions between variants of
ERAP1 and the corresponding disease-linked HLA alleles further
implicate peptide handling in the immunopathology of these
disorders.5,6 Much effort has therefore been dedicated to under-
standing the impact of ERAP1 polymorphisms on the naturally
presented epitope repertoire.8,9,33 However, previous studies
have not addressed the physiological relevance of these effects
on the immune response to exogenous antigens, for example
in the context of viral infections. We identified 2 hypoactive
ERAP1 allotypes in a donor with acute HCV infection. Donor
MM expressed 4 distinct HLA class I allotypes (A*01:01,
A*26:01, B*08:01, and B*27:05), all of which have been shown
to present HCV-derived epitopes that reproducibly elicit hierar-
chical CD8+ T cell responses.17,26,28,32 In contrast to these classi-
cal immune profiles, CD8+ T cells from donor MM targeted
either longer versions of the typically immunodominant
9-mer epitopes or novel 10-mer or 11-mer epitopes, character-
ized here for the first time. These results suggested that the
relatively subtle effects of ERAP1 polymorphisms in vitro pro-
foundly influenced the antigen-specific CD8+ T cell repertoire
in vivo.
Presentation of the B*27:05-restricted 11-mer epitope
GRAAICGKYLF was reduced only slightly in 293T E1KO cells har-
boring active prototype control ERAP1*002 relative to 293T
E1KO cells expressing the hypoactive donor MM allotypes
ERAP1*001 and ERAP1*014. Nonetheless, GRAAICGKYLF-
specific CD8+ T cells vastly outnumbered GRAAICGKY-specific
CD8+ T cells in donor MM. These divergent in vitro and in vivo
observations suggested a degree of leakiness in the ERAP1 sys-
tem, enabling the presentation of epitopes spanning different
lengths, which subsequently elicited a highly focused CD8+ T
cell response. Minor differences in antigen presentation were
therefore sufficient to invert the archetypal immunodominance
hierarchy in donor MM. In clinical terms, donor MM had no his-
tory of severe autoinflammatory disorders, but suffered from
protracted viral infections during childhood and developed mild
psoriasis on completion of this study. It therefore remains to be
determined how the corresponding ERAP1 allotypes impact
adaptive immunity beyond the context of HCV.
Despite the presence of several favorable prognostic indica-
tors (symptomatic course of infection, IL28B/IFNL4 genotype
CC, and expression of HLA-B*27), donor MM failed to clear the
virus and developed persistent low-level infection with HCV.
Although it is tempting to link this outcome with the hypoactive
ERAP1 allotypes and the skewed repertoire of HCV-specific CD8+
T cells, there was no direct evidence for a causal association
between these variables. Moreover, longitudinal sequence vari-
ations emerged in 2 of the 3 NS3-derived epitopes targeted in
donor MM, consistent with mutational escape: K1386R in the
HLA-A*26:01-restricted 11-mer epitope NS31383-1393 and
L1403F in the HLA-B*08:01-restricted 9-mer epitope
NS31395-1403. This observation suggested a potential role for
viral adaptation in the outcome of infection, but equivalent dataJournal of Hepatology 20were not available for targeted NS5B-derived epitopes, in part
due to the persistent low-level viremia in donor MM. However,
previous studies have demonstrated an association between
ERAP2 polymorphisms and resistance to HIV-1.34,35 In addition,
the ERAP1 polymorphism I276M (rs26618 T>C) was found to be
enriched in individuals with chronic HCV infection relative to
healthy controls.36 The non-risk residue was present at this
position in both ERAP1 allotypes expressed by donor MM. It is
also notable that CD8+ T cell responses to the 11-mer epitopes
HRFAPPCKPLL and GRAAICGKYLF were not detected in a cohort
of 10 HLA-B*27+ patients with chronic HCV genotype 1 infection
(data not shown). Rare combinations of ERAP1 allotypes may
therefore shape the repertoire of CD8+ T cell epitopes more dis-
tinctly than common variants of ERAP1.7
The peptide trimming function of ERAP1 can be profoundly
altered by the allotype expressed.37,38 These allotypic differ-
ences lead to a significantly altered peptide repertoire presented
at the cell surface, which as observed for patient MM, may affect
the presentation of immunodominant HCV epitopes, and thus,
CD8+ T cell responses. In addition to peptide trimming, ERAP1
has been suggested to function in the shedding of the cytokine
receptors IL-6R, TNFR1, and IL-1RII.39 These cytokines (IL-6, TNF,
IL-1) are important in inflammatory responses to viral infection.
It is not currently known how ERAP1 works to facilitate cyto-
kine receptor shedding, as it does not possess any ectodomain
cleavage activity.39 However, ERAP1 binds to the receptors
and may therefore act as an important bridge to promote cyto-
kine receptor cleavage through a third party. The cytokine
receptor cleavage activity was not examined in this study,
although it is tempting to speculate that allotype variants may
have differential functional capacities in this pathway. This
may alter levels of cytokine receptor shedding and levels of
these receptors at the cell surface and in serum as previously
observed for ERAP1 with reduced function, which resulted in
higher levels of IL-1b, TNF and IL-6,40 modulating the inflamma-
tory environment in infection.
In conclusion, we have demonstrated that hypoactive ERAP1
allotypes can impact the repertoire of epitopes targeted by
antigen-specific CD8+ T cells in a relevant human viral infection,
thereby supporting the general concept that peptide handling
underlies the immunopathogenesis of HLA class I-associated
autoinflammatory disorders. Further studies are therefore war-
ranted to explore similar phenomena in other clinical settings,
especially where disease susceptibility has been genetically
linked with functional polymorphisms in ERAP1.
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